BCYC FY2025 EPS Estimate Lifted by Cantor Fitzgerald

Bicycle Therapeutics plc (NASDAQ:BCYC) – Analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for Bicycle Therapeutics in a note issued to investors on Wednesday, February 26th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($3.49) per share for the year, up from their prior estimate of ($4.24). The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.10. The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company’s revenue for the quarter was down 30.2% on a year-over-year basis. During the same period in the prior year, the business earned ($1.16) EPS.

Other research analysts have also issued research reports about the company. Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday. Stephens restated an “equal weight” rating and set a $15.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. JMP Securities decreased their price target on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th. B. Riley dropped their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.14.

Bicycle Therapeutics Price Performance

BCYC stock opened at $11.03 on Friday. Bicycle Therapeutics has a 1 year low of $10.91 and a 1 year high of $28.67. The firm has a 50-day moving average of $13.35 and a 200 day moving average of $19.46. The company has a market cap of $761.62 million, a P/E ratio of -3.35 and a beta of 0.93.

Insider Activity

In other Bicycle Therapeutics news, CEO Kevin Lee sold 9,038 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $127,345.42. Following the transaction, the chief executive officer now owns 495,026 shares in the company, valued at approximately $6,974,916.34. This represents a 1.79 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Travis Alvin Thompson sold 2,686 shares of Bicycle Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $15.00, for a total transaction of $40,290.00. Following the completion of the sale, the chief accounting officer now owns 32,146 shares of the company’s stock, valued at $482,190. This represents a 7.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,677 shares of company stock worth $392,413 over the last 90 days. 8.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Assetmark Inc. bought a new position in shares of Bicycle Therapeutics during the 3rd quarter valued at $34,000. Barclays PLC lifted its holdings in Bicycle Therapeutics by 878.3% in the fourth quarter. Barclays PLC now owns 2,612 shares of the company’s stock valued at $37,000 after acquiring an additional 2,345 shares during the period. Avior Wealth Management LLC purchased a new position in Bicycle Therapeutics in the fourth quarter worth about $57,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after purchasing an additional 2,918 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after purchasing an additional 1,782 shares during the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.